Dear Editor: Phantom limb pain (PLP) and phantom limb sensation (PLS) describe sensation that is localized to a paralyzed or amputated appendage; PLP is painful, whereas PLS is not (1, 2) . There is little evidence from randomized controlled trials (RCTs) to guide treatment (3) , and the management of phantom limb continues to challenge clinicians. Traditionally, combined tricyclic antidepressants (TCAs) and opioids have been used effectively in the management of PLP, but increasing attention is being focused on the role of calcitonin (4) (5) (6) (7) . In a small, doubleblind RCT, Jaeger and Maier reported complete resolution of PLP in 76% of amputees at 1 week and and 71% of amputees at 2 years after treatment with intravenous calcitonin (6) . Related studies have shown that intranasal calcitonin is an effective analgesic agent in bone pain owing to osteoporosis and malignancy (8) (9) (10) . We describe the use of intranasal calcitonin for the treatment of PLS after spinal cord injury, which has not been previously described in the literature.
Case Report
Mr S, aged 60 years, with no psychiatric history, was the pedestrian victim of a hit-andrun accident that rendered him quadraplegic owing to a C5 lesion. Five days after admission, he complained of paresthesias and feelings of uncontrolled movement in his arms. Over the next 17 days, the symptoms interfered with his sleep and made him anxious, despite routine administration of diazepam and immovane. The psychiatric team was consulted and suggested that Mr S take a moderate dosage of clomipramine. The team was unable to give an opioid in combination with the TCA because he had experienced visual hallucinations on morphine earlier that week. Mr S complained that his PLS worsened, and the clomipramine was discontinued.
A trial of calcitonin was subsequently administered, initiated slowly owing to the potential for anaphylaxis as well as for less deleterious side effects such as nausea and vomiting. Intravenous calcitonin was not available at our centre, so intranasal calcitonin was started instead. After a trial of 1 IU calcitonin intradermally, Mr S was given 200 IU of intranasal calcitonin and reported an alleviation of PLS symptoms for several hours, during which he slept. Two days later, he received 400 IU of intranasal calcitonin, with only a transient improvement in symptoms.
Discussion
This case report on PLS does not support the beneficial effects of calcitonin on PLP reported in previous studies (2) . Our report differs from the literature in 2 important respects. First, intranasal administration has not been studied, and it is likely that the optimal dosage was not used in this patient's care. Further, previous studies all involve patients experiencing PLP symptoms after amputation, not PLS after spinal cord injury. This case report does highlight that intranasal calcitonin is well tolerated and convenient and may be effective as an acute pain reliever in patients who cannot tolerate traditional PLP or PLS pain medications. There continues to be a need for additional research to define the role of intranasal calcitonin in PLP pain management.
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The Use of Atomoxetine Adjunctively in Fibromyalgia Syndrome
Dear Editor: Fibromyalgia syndrome (FMS) is a chronic disease characterized by widespread musculoskeletal pain (1) . It is also accompanied by persistent fatigue, nonrestorative sleep, generalized morning stiffness, and multiple tender points (2) . FMS occurs more often in women than in men and has an overall prevalence rate of 1% in the population (3) . The pathophysiology of FMS is unknown; however, central monoaminergic transmission may be involved (4) . No single medication has been found to effectively treat all symptoms of FMS. Selective serotonin reuptake inhibitors (SSRIs), selective serotonin norepinephrine reuptake inhibitors (SNRIs), tricylic antidepressants, hypnotic agents, anticonvulsants, and analgesics have been used to treat the syndrome. The following cases discuss using atomoxetine adjunctively in FMS. To my knowledge, this is the first description of atomoxetine used in the pharmacologic treatment of FMS.
Case Report 1
Ms A is hispanic and aged 35 years. She was referred by her primary care physician for assistance with the pharmacologic management of her fibromyalgia. She had been diagnosed with fibromyalgia 1 year prior to consultation and took sertraline 150 mg daily and cyclobenzaprine 10 mg 3 times daily, as needed. She had a psychiatric history significant for a major depressive episode that had been in remission for about 2 years. She had no active symptoms associated with depression. Her biggest concerns were ongoing fatigue, coupled with a worsening of pain in her tender points, that interfered with her ability to work a consistent 40 hours weekly (she was able to work about 20 hours weekly). She had no other medical problems: recent laboratory test including a complete blood count, comprehensive metabolic panel, liver function test, thyroid-stimulating hormone, erythrocyte sedimentation rate, urinalysis, and pregnancy test were either within normal limits or negative. She did not want to discontinue taking sertraline because she had not tolerated other antidepressants (including venlafaxine and paroxetine) during her depressive episode. She gave informed consent to a trial of atomoxetine to target her symptoms and began atomoxetine 40 mg daily, which was titrated to 80 mg over 1 week with no significant side effects. Over the next 3 weeks, she began to note a reduction in pain and an increase in her energy level. She gradually began to increase her workweek by 5 hours Can J Psychiatry, Vol 49, No 7, July 2004 W 499
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